Celerion and the Korean Drug Development Fund (KDDF) have entered a collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea.
The agreement provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s expertise in early clinical research and bioanalysis, as well as external partner sites. The collaboration will support a sharing of knowledge between KDDF and Celerion, and will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market.
“We are delighted to collaborate with KDDF, and provide early clinical research expertise to support and strengthen the emerging pharmaceutical industry in South Korea,” said Susan Thornton Ph.D., president and chief executive officer of Celerion. “Our agreement with KDDF is further evidence of Celerion’s enthusiasm and commitment to contributing to the growth of South Korea’s biomedical research industry.”
“The KDDF is very happy to have established a partnership with Celerion. This collaboration is aligned to our vision to build effective partnerships between government, industry and academia,” said Dongho Lee MD, chief executive officer of KDDF. “Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation.”
Celerion Enters Korean Drug Development Pact
Published May 29, 2014
Related Breaking News
Related Online Exclusives